124I-MIBG PET/CT监测儿童复发神经母细胞瘤转移病灶
在7例接受131I-MIBG治疗前的患儿中比较123I-MIBG平面显像、SPECT/CT与124I-MIBG PET/CT,共评估8例患儿10次扫描。124I-MIBG PET/CT检出病灶数及Curie评分优于123I-MIBG平面显像和SPECT/CT,病灶检出差异有统计学意义。
要点
- 124I-MIBG PET/CT检出87个病灶,多于123I-MIBG平面显像的25个和SPECT/CT的32个。
- 124I-MIBG PET/CT与123I-MIBG平面显像及SPECT/CT的病灶检出差异均有统计学意义(P<0.0001)。
- 124I-MIBG有效剂量约为123I-MIBG的10倍,但因给药活度低(1.05 MBq/kg),实际有效剂量仅约2倍。
核心结论
- 首次在人体中使用低剂量124I-MIBG PET监测疾病负荷,其肿瘤检出能力优于123I-MIBG平面显像和SPECT/CT。
研究设计与样本
- 在131I-MIBG治疗前,7例患儿接受标准123I-MIBG显像(5.2 MBq/kg,含全身前后位平面显像、聚焦视野SPECT/CT)和全身124I-MIBG PET/CT(1.05 MBq/kg)。
- 治疗后2例患儿完成124I-MIBG PET/CT及配对的123I-MIBG平面显像和SPECT/CT,另1例患儿仅在治疗后接受124I-MIBG PET/CT。
- 共评估8例至少1个123I-MIBG阳性病灶的患儿、总计10次扫描;其中8对扫描的123I-MIBG与124I-MIBG检查间隔在1个月内。
- 记录123I-MIBG与124I-MIBG扫描的病灶位置、总病灶数和Curie评分;对5例完成至少3次124I-MIBG PET/CT的患儿估算124I-MIBG有效剂量。
主要发现
- 123I-MIBG全身平面显像、聚焦视野SPECT/CT和全身124I-MIBG PET分别检出25个、32个和87个病灶。
- 124I-MIBG PET/CT与123I-MIBG平面显像的病灶检出差异有统计学意义(P<0.0001),与123I-MIBG SPECT/CT的差异也有统计学意义(P<0.0001)。
- 10例患者中有6例的124I-MIBG PET/CT Curie评分高于123I-MIBG平面显像和SPECT/CT。
- 124I-MIBG PET/CT对全身病灶(包括胸部、脊柱、头颈部和四肢)的检出更好。
- 患者个体化124I-MIBG的有效剂量估计约为123I-MIBG的10倍;但鉴于给予的124I-MIBG活度很低(1.05 MBq/kg),尽管半衰期差异大(100 vs. 13.2 h),有效剂量仅约为123I-MIBG的2倍。
关键数值与推荐
- 123I-MIBG给药活度为5.2 MBq/kg,124I-MIBG给药活度为1.05 MBq/kg。
- 124I-MIBG与123I-MIBG半衰期分别为100 h和13.2 h。
- 124I-MIBG PET/CT检出87个病灶,123I-MIBG平面显像检出25个,SPECT/CT检出32个。
- 124I-MIBG PET/CT与123I-MIBG平面显像及SPECT/CT的病灶检出差异均P<0.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The metaiodobenzylguanidine (MIBG) scan is one of the most sensitive noninvasive lesion detection modalities for neuroblastoma. Unlike 123I-MIBG, 124I-MIBG allows high-resolution PET. We evaluated 124I-MIBG PET/CT for its diagnostic performance as directly compared with paired 123I-MIBG scans. Methods: Before 131I-MIBG therapy, standard 123I-MIBG imaging (5.2 MBq/kg) was performed on 7 patients, including whole-body (anterior-posterior) planar imaging, focused-field-of-view SPECT/CT, and whole-body 124I-MIBG PET/CT (1.05 MBq/kg). After therapy, 2 of 7 patients also completed 124I-MIBG PET/CT as well as paired 123I-MIBG planar imaging and SPECT/CT. One patient underwent 124I-MIBG PET/CT only after therapy. We evaluated all 8 patients who showed at least 1 123I-MIBG-positive lesion with a total of 10 scans. In 8 pairs, 123I-MIBG and 124I-MIBG were performed within 1 mo of each other. The locations of identified lesions, the number of total lesions, and the curie scores were recorded for the 123I-MIBG and 124I-MIBG scans. Finally, for 5 patients who completed at least 3 PET/CT scans after administration of 124I-MIBG, we estimated the effective dose of 124I-MIBG. Results:123I-MIBG whole-body planar scans, focused-field-of-view SPECT/CT scans, and whole-body 124I-MIBG PET scans found 25, 32, and 87 total lesions, respectively. There was a statistically significant difference in lesion detection for 124I-MIBG PET/CT versus 123I-MIBG planar imaging (P < 0.0001) and 123I-MIBG SPECT/CT (P < 0.0001). The curie scores were also higher for 124I-MIBG PET/CT than for 123I-MIBG planar imaging and SPECT/CT in 6 of 10 patients. 124I-MIBG PET/CT demonstrated better detection of lesions throughout the body, including the chest, spine, head and neck, and extremities. The effective dose estimated for patient-specific 124I-MIBG was approximately 10 times that of 123I-MIBG; however, given that we administered a very low activity of 124I-MIBG (1.05 MBq/kg), the effective dose was only approximately twice that of 123I-MIBG despite the large difference in half-lives (100 vs. 13.2 h). Conclusion: The first-in-humans use of low-dose 124I-MIBG PET for monitoring disease burden demonstrated tumor detection capability superior to that of 123I-MIBG planar imaging and SPECT/CT.
引用
- Aboian MS, Huang SY, Hernandez-Pampaloni M, et al. 124I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma. J Nucl Med. 2020. PMID: 32414950. doi:10.2967/jnumed.120.243139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。